New York, February 2, 2026, 14:52 (ET) — Regular session underway.
- Shares climbed 5.7% to $72.02 in afternoon trading, hitting a session peak of $73.77
- January update highlighted a preliminary revenue range for 2025 and scheduled a February earnings call to discuss full results
- Next up: U.S. Motiva ramp, FDA breast reconstruction review, and guidance for 2026
Shares of Establishment Labs Holdings Inc (ESTA) climbed 5.7% to $72.02 during Monday’s afternoon session, after peaking at $73.77. Roughly 432,000 shares traded hands. The Costa Rica-based medical technology and aesthetics firm moved higher alongside gains in the S&P 500 and Nasdaq Composite, which rose about 0.7% and 0.8%, respectively. (Reuters)
Investors have been focused on a Jan. 12 update, when the company released preliminary 2025 figures and flagged a February earnings call for the full breakdown. It forecasted revenue for the quarter ending Dec. 31 between $64 million and $65 million, with $17 million to $17.5 million coming from U.S. Motiva sales. Full-year revenue was projected between $210.5 million and $211.5 million, including $45.4 million to $45.9 million from Motiva sales in the U.S. The company also estimated year-end cash around $75.5 million. “We had an excellent finish to 2025, with record quarterly revenue,” said Peter Caldini. He added they expect to turn free cash flow positive later this year and continue to generate “positive adjusted EBITDA,” while cautioning the numbers remain unaudited and subject to change. (SEC)
This is crucial now as the U.S. rollout begins to impact the figures, with the stock reacting sharply to each cash usage update. The February call will likely recalibrate 2026 forecasts, especially regarding the spending needed to grow sales and maintain pricing power.
The stock has risen roughly 11% from its close of $64.95 on Jan. 27, finishing Friday at $68.15, MarketScreener data show. (MarketScreener)
On Dec. 29, Establishment Labs announced it had submitted its Motiva implants to the U.S. Food and Drug Administration (FDA) for approval in primary and revision breast reconstruction. This move expands on the company’s September 2024 FDA clearance for breast augmentation. “Expanding our FDA approval from breast augmentation to reconstruction is an important step forward for women’s health,” said Jeff Ehrhardt. Mark Clemens from The University of Texas MD Anderson Cancer Center noted that innovation in this field has been gradual and praised technologies that “address real clinical limitations.” Since the 2024 approval, Establishment Labs said it has sold more than 60,000 Motiva implants in the U.S. (Establishment Labs)
Adjusted EBITDA measures earnings before interest, taxes, depreciation, and amortization, leaving out certain items; investors treat it as a rough indicator of core operating performance. Free cash flow, meanwhile, shows cash generated after capital expenditures, serving as a crucial test of whether growth is self-funded.
However, the January numbers haven’t been audited, and the reconstruction filing leaves regulators the option to request additional information or extensions. Should demand for elective procedures slow down or costs climb faster than forecasted, the stock’s rally could stall abruptly.
Investors are now eyeing the February earnings call, waiting for full 2025 results and clearer guidance on 2026 targets alongside updates on the FDA review. Until that happens, the focus stays on how confident traders feel about the Motiva ramp.
